Servier today announced it will present new and updated data at the 22nd International Symposium on Pediatric Neuro-Oncology ...

Personalized Medicine. 2013;10(4):405-412. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with ...

The transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases ...

Metastases develop in 10–15% of patients with cutaneous melanoma and there is no evidence from phase-III trials that systemic treatment prolongs survival, nor is there an effective adjuvant therapy ...

Brain tumors are the most common solid tumor of children and the most common cause of cancer-related deaths. The poor overall outcome of this patient population results from three major issues: 1) The ...

Researchers have discovered a signaling pathway between cytokines and BRAF that promotes tumor growth. The finding could provide a potential therapeutic target. The protein BRAF is a key player in the ...

After decades of stagnation, recent therapeutic advances in melanoma seem on the horizon. The discovery of the genetic underpinnings of this historically refractory disease has exposed potential ...

The BRAF mutation affects a small percentage of non-small cell lung cancer (NSCLC) cases, making the cancer more difficult to treat. In recent years, advances in treatment have helped to improve ...

Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from ...

Researchers have identified a range of genetic alterations in glioma brain cancers that will help them to understand how different mutations in one particular gene interact with other gene alterations ...